Plant Engineering Manufacturing Plant for New Pharma Excipient Viscomedi Completed

Source: Press release Shoko 1 min Reading Time

Related Vendors

Shoko has recently announced that the manufacturing plant for the new pharmaceutical excipient “Viscomedi” has been completed in South Korea, and full-scale commercial production also began in February 2026.

Shoko Co. has announced that, following the sales framework agreement announced in June 2025 with Hannong Chemicals, the manufacturing plant for the new pharmaceutical excipient “Viscomedi” has been completed. (Source:  Hannong Chemicals)
Shoko Co. has announced that, following the sales framework agreement announced in June 2025 with Hannong Chemicals, the manufacturing plant for the new pharmaceutical excipient “Viscomedi” has been completed.
(Source: Hannong Chemicals)

Tokyo/Japan – Shoko Co., a comprehensive commodity trading firm engaged in three business domains—chemicals, plastics, and metal & ceramics—is pleased to announce that, following the sales framework agreement announced in June 2025 with Hannong Chemicals, the manufacturing plant for the new pharmaceutical excipient “Viscomedi” has been completed, and full-scale commercial production commenced in February 2026.

Hannong Chemicals has been developing a Partially Neutralized Polyacrylate product for pharmaceutical applications and has officially named it “Viscomedi.” The company has been advancing development with the aim of providing a new option for pharmaceutical applications. The main production facilities were completed in November last year, followed by equipment testing and regulatory compliance activities.

As of June 2026, Shoko and Hannong Chemicals are in the final stages of negotiations toward a definitive agreement based on the existing sales framework agreement. Upon conclusion of the agreement, Shoko plans to act as the global exclusive distributor for “Viscomedi”.

(ID:50887898)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent